Depression has been associated with a low-grade chronic inflammatory state, suggesting a potential therapeutic role for anti-inflammatory agents. Fisetin is a naturally occurring flavonoid in strawberries that has anti-inflammatory activities, but whether fisetin has antidepressant effects is unknown. In this study, we exposed mice to spatial restraint for 2 weeks with or without treatment with fisetin. Immobility time in the forced swimming and tail suspension test after this restraint increased in the untreated group, but this increase did not occur in the fisetin group. We administered fisetin to Abelson helper integration site-1 (Ahi1) knockout mice, which have depressive phenotypes. We found that fisetin attenuated the depressive phenotype of these Ahi1 knockout mice. We
further investigated the potential mechanism of fisetin's antidepressant effects. Because TrkB is a critical signaling pathway in the mechanisms of depression, we examined whether phosphorylated TrkB was involved in the antidepressant effects of fisetin. We found that fisetin increased phosphorylated TrkB level without altering total TrkB; this increase was attenuated by K252a, a specific TrkB inhibitor. Taken together, our results demonstrated that fisetin may have therapeutic potential for treating depression and that this antidepressant effect may be mediated by the activation of the TrkB signaling pathway. Keywords: antidepressant, behaviors, depression, fisetin, TrkB. J. Neurochem. (2017) 143, 561--568. Depression has become one of the leading causes of morbidity and mortality worldwide. (Dwyer et al. 2011; Kumar et al. 2011) . Currently available pharmacological treatments for depression include selective serotonin reuptake inhibitors and monoamine oxidase inhibitors, which have antidepressant effects by the increased release of monoamines such as serotonin and noradrenaline (Mao et al. 2008) . However, clinical data have demonstrated that these antidepressants have substantial side effects (Duman et al. 2007; Zhu et al. 2016) . Thus, there is an urgent need to find safer new therapeutic agents.
Fisetin, abundant in strawberries and vegetables, belongs to the flavonoid class of polyphenols. Fisetin has been shown to possess antioxidant, anti-inflammatory, and neuroprotective properties (Brash and Havre 2002; Ross and Kasum 2002; Maher 2008) . Because of these properties, fisetin has been considered as a potential effective agent in a variety of neurological disorders such as stroke, Huntington's disease, and Alzheimer's disease (Maher et al. 2006) . However, the antidepressant effects of fisetin have not been explored. In theory, fisetin's anti-inflammatory effects are able to suppress the chronic low-level inflammatory state that has been observed in depressive patients (Kohler et al. 2016) .
Depression is closely associated with a series of physiological abnormalities including decreased tropomyosin receptor kinase B (TrkB) phosphorylation (Zhang et al. 2016b) . Previous studies found that many antidepressants increase TrkB phosphorylation and activate downstream signaling pathways (Saarelainen et al. 2003; Rantamaki et al. 2007; Xu et al. 2010) . Animal experiments also demonstrated that brain-derived neurotrophic factor/TrkB signaling is impaired in mice with depressive phenotypes (Xu et al. 2010; Cai et al. 2015) . In addition, the brainderived neurotrophic factor/TrkB signaling plays an important role in the rapid antidepressant effects (Zhang et al. 2016a; Adachi et al. 2017; Hou et al. 2017; Jiang et al. 2017; Sussman et al. 2017; Zhou et al. 2017) . Therefore, the TrkB signaling pathway provides a new therapeutic target for depression. Recent studies showed that many flavonoids such as evodiamine are activators of TrkB that increase phosphorylated TrkB (pTrkB) level and have antidepressant effects (Jang et al. 2010; Jiang et al. 2015; Yan et al. 2016) . In addition, mice with depressive symptoms have decreased levels of pTrkB and TrkB (Wang et al. 2015) . Therefore, we examined whether the underlying mechanism of fisetin are related to TrkB activation.
In recent studies, Ahi1 mutations have been demonstrated to be associated with a series of psychiatric diseases (Katic et al. 2014; Ren et al. 2014b; Elsayed et al. 2015) . Animal experiments also confirmed that Ahi1 knockout (KO) mice showed stable depressive behaviors and is a useful depressive mouse model to screen antidepressant drugs (Ren et al. 2014b) . In this study, the antidepressant effect of fisetin was examined in Ahi1 KO mice and spatial restraint stressinduced depressive mice.
Materials and methods

Animals
Male adult ICR mice (RRID:IMSR_RBRC05979; 20-23 g, 25°C) were bought from SLAC Company (Shanghai, China). Ahi1 loxp/loxp mice (RRID: IMSR_CRL:27; C57BL/6; age 2 month) were generated as described previously (Ren et al. 2014b) . The floxed mice (Ahi1 loxp/loxp ) were crossed with EIIaCre mice carry a Cre transgene under the control of the EIIa promoter and produced heterozygous Ahi1 KO mice. Two heterozygous Ahi1 KO mice were used to generate homozygous Ahi1 KO mice. All animal procedures and experiments in this study were approved by the University Committee on Animal Care of Soochow University and were complied with the ARRIVE guidelines and the National Institutes of Health guide for the care and use of Laboratory animals. This study was not pre-registered.
Experimental design
The experimental outline is shown in Fig. 1 . In the first set of the study (Fig. 1a) , ICR mice were randomly assigned to four groups: (i) control Fig. 1 Experimental outline. In the spatial restraint stress-induced depressive mouse model, fisetin was administrated intraperitoneally once daily for 2 weeks. The tail suspension test and the forced swimming test were performed to determine the antidepressant effects of fisetin (a). For depressive Ahi1 knockout mice, mice were treated with vehicle or fisetin for 3 weeks followed by behavioral tests (b). K252a was administrated intraperitoneally once daily during the last 3 days in the spatial restraint stress-treated mice; behavioral tests and western blot were further performed (c).
group (n = 7); (ii) fisetin alone group (n = 9); (iii) stress group (n = 9); (iv) fisetin-treated stress group (n = 10). After mice were undertaken 2-week's stress, they were treated with or without fisetin for 2 weeks. These mice were then subjected to behavioral tests. In the second set of the study (Fig. 1b) , Ahi1 KO mice were randomly assigned to two groups: Ahi1 KO group (n = 8) and fisetin-treated Ahi1 KO group (n = 6). In fisetin-treated Ahi1 KO group, the mice received fisetin treatment for 3 weeks. In the third set of the study (Fig. 1c) , ICR mice were randomly assigned to five groups: (i) Control group (n = 8); (ii) Control group + fisetin (n = 9); (iii) Stress group (n = 10); (iv) Stress group + fisetin (n = 10); (v) Stress group + fisetin + K252a (n = 8). These mice were killed at day 28 after fisetin treatment for 2 weeks and K252a for 3 days. In each experiment, mice were randomly assigned according to a randomization table. The investigators involved in data analysis were blinded to sample identity. No mice was excluded in this study.
Spatial restraint stress
Chronic spatial restraint stress is widely used to produce depressive phenotypes in animals (Kim et al. 2015; Zhang et al. 2015) . Mice were put into a 50-mL tube daily for 2 h in the morning every day. These mice were restrained in tubes and cannot move (Zhang et al. 2015) . After about 2 weeks, these mice showed depressive behaviors and were randomly divided into four groups: control group, fisetin alone group, stress group, and fisetin-treated stress group. Mice were treated with vehicle or fisetin daily for 2 weeks and behavioral tests were then determined.
Tail suspension test
The tail suspension test (TST) was performed as described previously (Porsolt et al. 1977) . Animal tails were tapped 50 cm over a table by a medical adhesive tape. Animal behaviors were recorded in a 6-min video. Immobility time was recorded manually with a stopwatch by a trained person who was blind to the genotypes or the groups of mice. Pretest training of mice was not performed.
Forced swimming test
The forced swimming test (FST) was performed as described previously (Zhang et al. 2015) . Mice were placed in a 30-cm diameter and 50-cm height glass cylinder that filled with water in 30 cm depth (approximately 25°C). Immobility time was recorded when they stopped struggling; floating on the water and the motion of keeping their head above the water was also counted. A trained person who was blind to the genotypes or the groups of the mice calculated immobility time based on a 6-min video. Pretest training of mice was not performed. were determined in mice. *p < 0.05 versus control group. N = 20 mice. Mice were treated with fisetin (5 mg/kg) or vehicle for 2 weeks. The TST (c) and the FST (d) were performed at 1 and 2 weeks after treatments. *p < 0.05 versus stress group. N = 7-10 mice.
Animal drug administration
Fisetin (Sigma-Aldrich, Saint Louis, MO, USA) was sonicated as a suspension in 0.25% carboxymethylcelluose sodium salt (SigmaAldrich) and 0.2% Tween-80. This dosage of fisetin (5 mg/kg body weight) chosen in this study was based on the previous study (Sahu et al. 2016) . K252a was purchased from Sigma-Aldrich Corporation and dissolved in 1% dimethyl sulfoxide. The dosage of K252a (25 lg/kg) was chosen based on previous report (Wang et al. 2015) . K252a was injected intraperitoneally (i.p.) for 3 days. Control mice were injected with same volume of vehicle.
PC12 cell culture and drug administration PC12 cells (RRID: CVCL_0481, Code at ICLAC website: 88022401) were maintained in Dulbecco's modified Eagle's medium (Hyclone, Logan, UT, USA) containing 10% fetal bovine serum (Gibco BRL Co. Ltd., USA), 100 IU/mL penicillin G sodium, and streptomycin sulfate. When PC12 cells reached 50-60% of confluence, drug administration was performed. The drug dosage (40 lM) was consistent with the previous report (Su et al. 2017) . After 48 h, the cells were collected for western blotting analysis.
Western blotting analysis
After behavioral tests, different brain tissues including the hippocampus, the brainstem, and the hypothalamus were collected. Samples were homogenized in the presence of lysis buffer and the resulting homogenate was centrifuged at 4°C. Subsequently, the supernatant was transferred to a new tube and protein concentration was determined by the bicinchoninic acid method (Bradford 1976) . After protein samples were heated at 96°C for 10 min, the proteins were separated on 8% sodium dodecyl sulfate-polyacrylamide gel and subsequently electro-transferred to nitrocellulose membranes. The membrane blot was incubated with antibodies against pTrkB (RRID: AB_2236299; 1 : 1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), TrkB (RRID: AB_2155274; 1 : 2000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and glyceraldehyde 3-phosphate dehydrogenase (RRID: AB_627679; 1 : 20 000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal anti-betatubulin (RRID: AB_477556; 1 : 20 000; Sigma-Aldrich, Saint Louis, MO, USA) at proportional dilution overnight with shaking at 4°C. After washes, the blot was incubated with the secondary antibodies for 1 h at 25°C. Protein signals were visualized using the Immobilon TM Western Chemiluminescent horseradish peroxidase Fig. 3 Fisetin rescued depression-like behaviors in Ahi1 knockout (KO) mice. Immobility time in the tail suspension test (TST) was examined in control and Ahi1 KO mice at the age of 2-3 m (a). Immobility time in the forced swimming test (FST) was examined in control and Ahi1 KO mice (b). *p < 0.05 versus control group. N = 14-16 mice. Ahi1 KO mice were treated with fisetin (5 mg/kg) or vehicle daily for 3 weeks. The TST was performed at 1, 2, and 3 weeks after fisetin treatments (c). The FST was examined at 1, 2, and 3 weeks after fisetin treatments (d). *p < 0.05 versus Ahi1 KO group. N = 6-8 mice.
Substrate (ECL) and detected on medical X-ray films. The ratio of band intensities to beta-tubulin (RRID: AB_477556; 1 : 20 000; Sigma-Aldrich, Saint Louis, MO, USA) or glyceraldehyde 3-phosphate dehydrogenase (RRID: AB_627679; 1 : 20 000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used to reduce sample-loading errors.
Statistical analysis
All data were expressed as the mean AE SEM. Sample sizes were determined based on previous studies (Ren et al. 2014a; Wang et al. 2017a ). An assessment of the normality of data was carried out by the Shapiro-Wilk test before the statistical tests. The GraphPad Prism software (Version 6; La Jolla, CA, USA) was used to perform statistical analyses. Student's t-test was used to determine the differences between two groups. The differences among multiple groups were determined with a one-way analysis of variance followed by Tukey's multiple comparison tests or two-way analysis of variance followed by Bonferroni post hoc tests. p < 0.05 were considered as statistically significant.
Results
Fisetin administration reversed depression-like behaviors induced by spatial restraint stress in mice
In this study, we examined the antidepressant effect of fisetin in the spatial restraint stress-induced mouse model. After 2 weeks of spatial restraint stress, the immobility time was significantly increased in both TST (p < 0.05, Fig. 2a ) and FST (p < 0.05, Fig. 2b ), indicating that the stressed mice had a depressive-like phenotype. The control mice and stressed mice were treated with fisetin (5 mg/kg body weight) or vehicle daily. The behavioral tests were examined at 1 and 2 weeks after the treatment. In the TST, fisetin treatment did not decrease the immobility time in control mice; however, fisetin treatment significantly decreased the immobility time in the stressed mice at 1 and 2 weeks after treatment (F(1,31) = 109.5, p < 0.01; Fig. 2c ). Similar to the TST, fisetin also markedly decreased the immobility time in the stressed mice at 1 and 2 weeks after treatment in the FST (F(1,31) = 12.47, p < 0.01; Fig. 2d ). Therefore, our data showed that fisetin had rapid antidepressant effects on depressive behaviors induced by spatial restraint stress.
Fisetin attenuated depression-like behaviors in Ahi1 KO mice To further identify the antidepressant effects of fisetin, Ahi1 KO mice were used in this study. Consistent with our Fig. 4 Fisetin increased phosphorylated TrkB level in the hippocampus in mice. Mice were treated with fisetin (5 mg/kg) or vehicle once and the pTrkB level was examined at different time points after fisetin treatment (0, 9, and 24 h) by western blot analysis (a). The densities of pTrkB and TrkB bands were quantified and then the ratios of pTrkB to TrkB were determined (b). *p < 0.05 versus 9 h. N = 3 hippocampal samples. and/or fisetin (50 lM) for 48 h. The levels of pTrkB and TrkB were determined by western blot analysis (a). The densities of pTrkB and TrkB bands were quantified and the ratios of pTrkB to TrkB were determined (b). *p < 0.05 versus control group; #p < 0.05 versus Dex group. N = 3 samples.
previous study, Ahi1 KO mice exhibited the increased immobility time in the TST (p < 0.05, Fig. 3a ) and the FST (p < 0.05, Fig. 3b ) compared with the control mice (Ren et al. 2014b ). Ahi1 KO mice were randomly assigned into two groups and treated with or without fisetin. Our results indicated that fisetin did not decrease the immobility time at 7 days after treatment in the TST (p > 0.05, Fig. 3c ) and in the FST (p > 0.05, Fig. 3d) ; however, fisetin treatment significantly decreased the immobility time in the TST (p < 0.05, Fig. 3c ) and the FST (p < 0.05, Fig. 3d ) at 2 and 3 weeks after treatment compared with vehicle treatment.
Fisetin treatment increased pTrkB in the hippocampus of mice It is unclear whether fisetin activates TrkB to provide the antidepressant effect in mice; therefore, we examined the activation of TrkB after fisetin treatment at different time points. Our results demonstrated that total TrkB levels were not changed after fisetin treatment within 24 h (p > 0.05, Fig. 4a ). However, compared with 0 h time point, fisetin significantly increased pTrkB levels in the hippocampus at 9 h after treatments (p < 0.05) and restored pTrkB to normal levels at 24 h after treatments (p > 0.05, Fig. 4a and b) .
Fisetin treatment attenuated dexamethasone-induced decrease in TrkB signaling pathways in PC12 cells
Previous studies demonstrated that patients with major depression have high glucocorticoid levels, which downregulate the TrkB signaling pathway (Zung et al. 1965; Ridder et al. 2005) . To further examine the direct effects of fisetin on cellular TrkB signaling, we treated PC12 cells for 48 h with dexamethasone (Dex) and/or fisetin. As expected, Dex treatment markedly decreased the ratio of pTrkB to TrkB (p < 0.05, Fig. 5a ). Fisetin alone treatment did not increase the ratio of pTrkB to TrkB (p > 0.05); however, compared with Dex group, fisetin treatment significantly increased the pTrkB level and the ratio of pTrkB to TrkB (F(1,8) = 18.94, p < 0.01; Fig. 5a and b). TrkB inhibitor K252a blocked TrkB activation and diminished the antidepressant effects of fisetin in mice Although our data demonstrated the activation of TrkB by fisetin treatment, it is unknown whether TrkB activation is involved in the antidepressant mechanisms of fisetin. To resolve this question, we treated restraint stress-induced depressive mice with fisetin and/or K252a (25 lg/kg body weight), a specific inhibitor of TrkB. In stressed mice, the pTrkB level and the ratio of pTrkB to TrkB in the hippocampus significantly decreased (F(1,8) = 9.825, p < 0.01; Fig. 6a and b) . Fisetin treatment for 2 weeks significantly increased the pTrkB level and the ratio of pTrkB to TrkB (F(1,8) = 9,825, p < 0.05; Fig. 6a and b) . TrkB inhibitor K252a blocked TrkB activation and reversed the effect of fisetin on the pTrkB level (F(1,8) = 9.825, p < 0.05; Fig. 6a and b). Consistent with this, TrkB inhibitor K252a diminished the antidepressant effects of fisetin and increased the immobility time in the TST (F(1,33) = 21.95, p < 0.01; Fig. 6c ) and the FST (F(1,33) = 34.12, p < 0.01; Fig. 6d ).
Discussion
Fisetin (3-3 0 -4 0 -7-tetrahydroxyflavone), a plant flavonol found in fruits and vegetables (Arai et al. 2000) , has been reported to play an important role in psychiatric disorders (Yu et al. 2016) . Recent studies also demonstrated that fisetin improves memory by promoting neurogenesis in mice (Ishige et al. 2001; Maher et al. 2006) . In addition, fisetin has antioxidant, anti-inflammatory, and neuroprotective activities (Brash and Havre 2002; Ross and Kasum 2002; Maher 2008 ). Therefore, fisetin has multiple functions in different diseases. In this study, we used spatial restraint-stressed mice and Ahi1 KO mice to determine the antidepressant effects of fisetin. Our results indicated that fisetin provided a rapid antidepressant action within 1-2 weeks (Figs 2 and 3) . Consistent with the previously demonstrated pro-neurogenesis effects of fisetin in the hippocampus (Wang et al. 2017b) , we found that fisetin increased the activation of TrkB signaling in the hippocampus (Fig. 4) . Furthermore, fisetin also increased cellular TrkB activation in PC12 cells, suggesting the activity of TrkB activator. In our in vitro and in vivo experiments, we found that treatment of fisetin increased TrkB phosphorylation.
Many members of the flavonoid family like 7,8-dihydroxyflavone and evodiamine strongly activate TrkB (Jang et al. 2010; Jiang et al. 2015) . 7,8-dihydroxyflavone, a small molecular chemical of flavonoid family, is considered a selective and high-affinity TrkB agonist. It provides a powerful therapeutic potential for various neurological diseases including stroke and Parkinson's disease. As a high potent TrkB agonist, 7,8-dihydroxyflavone demonstrated its antidepressant effects on depressive behaviors in mice (Liu et al. 2012) . As a member of flavonoid family, fisetin also showed rapid antidepressant effect in depressive mouse models.
In conclusion, we demonstrated the antidepressant effect of fisetin in depressive mouse models. We also show that these effects may be mediated by the activation of TrkB without altering total levels of TrkB.
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